AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT04183257 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: oral vitamin D
Description: oral Vitamin D 400IU will be given and will be escalated every 2 weeks.
Study NCT03661541 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Squaric Acid Dibutyl Ester
Description: 2% squaric acid dibutyl ester (SADBE) (Supplied by Squarex) is topically applied to the inner aspect of the upper arm of the subject and covered with Tegaderm. Subject is advised to wash it off after 3 hours.
Study NCT04444700 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Therapeutic anticoagulation
Description: The choice of low molecular weight heparin (LMWH) versus unfractionated heparin (UFH) will be at the clinician's discretion. LMWH options include: Tinzaparin, Enoxaparin or Dalteparin. UFH will be administered using a weight-based nomogram with titration according to center-specific institutional protocol.
Study NCT02160977 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: total knee arthroplasty
Study NCT02160977 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: total knee arthroplasty
Study NCT02595879 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: High-Dose Rate Brachytherapy
Description: Undergo HDR brachytherapy
Study NCT04061473 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo tablet
Description: 2 placebo tablets.~Standardized liquid meal Standardized liquid meal (200 ml) containing: 1,650 KJ, (394 kcal), carbohydrate 50%, protein 15%, fat 35% consisting of glucose (47.2 g + 2.8 g \[U-13C6\]-glucose), rapeseed oil (14.1 g), whey protein (15.2 g) and 1.5 g paracetamol.
Study NCT02595879 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Intensity-Modulated Radiation Therapy
Description: Undergo IMRT
Study NCT02595879 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Magnetic Resonance Imaging
Description: Undergo MRI
Study NCT03922750 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Insulin glargine U100
Description: Participants will receive s.c. injections of insulin glargine OD for 16 weeks
Study NCT01627431 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: Acetylsalicylic acid
Description: 100 mg once per day
Study NCT01627431 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: Clopidogrel
Description: 75 mg once per day
Study NCT02595879 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Pharmacological Study
Description: Correlative studies
Study NCT02595879 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Positron Emission Tomography
Description: Undergo FDG-PET/CT
Study NCT02595879 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Triapine
Description: Given IV and PO
Study NCT01918813 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: vancomycin, mupirocin ointment
Description: contact precautions, topical decolonization of MRSA by a bath with 4% chlorhexidine daily for 3-5 days
Study NCT02604667 — intervention group
Intervention type: OTHER
Intervention: Blood tests
Description: Study participants will undergo a single, peripheral blood draw. Blood specimens will be used to perform hematological biomarker testing and leukocyte RNA gene expression analysis.~Hematological biomarker testing will be performed to better elucidate the mechanisms of ischemic stroke in cancer patients and will include markers of coagulation, platelet function, and endothelial integrity. This analysis will occur at MSKCC.~Leukocyte RNA gene expression analysis will be performed to evaluate whether patients with cancer and stroke more often have cardioembolic mechanisms than patients with stroke and no cancer. This analysis will occur at the University of California, Davis where investigators have previously shown that differential RNA expression patterns can predict stroke subtypes.
Study NCT04289987 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: CVI-HBV-002
Description: Investigational Product
Study NCT04289987 — intervention group
Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: Normal Saline(placebo)
Description: Investigational Product
Study NCT02604667 — intervention group
Intervention type: OTHER
Intervention: Transcranial Doppler Microemboli Detection Study
Description: Study participants will undergo a single Transcranial Doppler Microemboli Detection Study at NYPH/WCMC or MSKCC within two weeks of enrollment. Both middle cerebral arteries will be insonated for 30 minutes by a trained technician or stroke neurologist certified in neurosonology using a fixed headset to assess for the rate and laterality of microemboli.
Study NCT04367194 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Neurorehabilitation
Description: After examination of the patients, the patients undergo neurorehabilitation. We use virtual reality therapy. Patients perform a submaximal load that is monitored by a polar clock. We develop endurance, coordination, sensory integration, visual and acoustic input, vestibular training, proprioception training.
Study NCT01513967 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: RPh201, botanical drug product
Description: SC administration at varying doses
Study NCT01079390 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: acupuncture
Description: patient will receive high dose, low dose or sham acupuncture treatment.
Study NCT01079390 — intervention group
Intervention type: DEVICE
Group type: PLACEBO_COMPARATOR
Intervention: acupuncture
Description: patient will receive high dose, low dose or sham acupuncture treatment.
Study NCT00159874 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sildenafil citrate
Description: Oral, subjects with body weight ≥8 - 20 kg: 20 mg 3 times a day (tid) subjects with body weight >20 - 45 kg: 40 mg 3 times a day (tid) subjects with body weight >45 kg: 80 mg 3 times a day (tid)
Study NCT00159874 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sildenafil citrate
Description: Oral,10 mg 3 times a day (tid), only subjects with body weight >20 kg
Study NCT00159874 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sildenafil citrate
Description: Oral, subjects with body weight ≥8 - 20 kg: 10 mg 3 times a day (tid); subjects with body weight >20 - 45 kg: 20 mg 3 times a day (tid); subjects with body weight >45 kg: 40 mg 3 times a day (tid)
Study NCT01436890 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Revamilast
Description: Tablet. Low dose, Once daily for 12 weeks
Study NCT01436890 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Revamilast
Description: Medium dose, Once daily for 12 weeks
Study NCT01513967 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: SC administration at varying doses
Study NCT01436890 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Revamilast
Description: High dose, Once daily for 12 weeks
Study NCT01436890 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo tablet in triple dummy format, Once daily for 12 weeks
Study NCT01313325 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Hippotherapy
Description: Children will receive treatment by a licensed physical therapist using hippotherapy as the treatment strategy. This includes sitting on a horse who's movement is controlled by a horse leader, with the PT directing the movements required of the horse, as well as supplying supplemental cues to the participant. Alternative positions (such as sitting backward and sideways) may also be used during the treatment session.
Study NCT01515254 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: lifestyle counseling, parental feeding
Description: Intervention group subjects will undergo a Feeding Dynamic Intervention (FDI). The intervention will be delivered in a closed group setting and will consist of 6 intervention sessions lasting 90 minutes each. Visits to physicians, WIC offices, nutrition program etc will be tracked. The subjects will undergo the energy regulation tests at baseline and 3 months. They will complete surveys and have their weight taken.
Study NCT01122680 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tiotropium bromide
Description: inhalation solution, dose of 1.25 mcg (2 puffs of 0.625 mcg)
Study NCT01122680 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: tiotropium bromide
Description: inhalation solution, dose of 2.5 mcg (2 puffs of 1.25 mcg)
Study NCT01122680 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: tiotropium bromide
Description: inhalation solution, dose of 5 mcg (2 puffs of 2.5 mcg)
Study NCT01122680 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: placebo inhalation solution
Study NCT00692237 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Sildenafil
Description: 100 mg daily (3 capsules/day)
Study NCT00692237 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo 100 mg (3 capsules/day)
Study NCT03683498 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Regulatory T-cell enriched infusion
Description: Enrichment of CD25hi regulatory T cells from CD8 and/or CD19 pre-depleted leukapheresis products.
Study NCT02570425 — intervention group
Intervention type: DEVICE
Group type: PLACEBO_COMPARATOR
Intervention: Training on BF Spiromax followed by SYMBICORT Turbohaler
Description: Training with a placebo comparator: Budesonide Formoterol (BF) Spiromax® device using a 6-level system to examine the number of levels required to acquire mastery of device at baseline and maintenance and mastery at 4 and 8 weeks after initial training.
Study NCT02570425 — intervention group
Intervention type: DEVICE
Group type: PLACEBO_COMPARATOR
Intervention: Training on SYMBICORT Turbohaler followed by BF Spiromax
Description: Training with a placebo comparator: SYMBICORT Turbohaler® device using a 6-level system to examine the number of levels required to acquire mastery of device at baseline and maintenance and mastery at 4 and 8 weeks after initial training.
Study NCT01579877 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Herbal extract granule
Description: The herbal extract granule, Yukmijihwang-tang granule, consists of 6 herbs. Ingredients: Rehmanniae Radix, Deoscoreae Radix, Corni Fructus, Hoelen, Alismatis Radix, Paeoniae Radicis Cortex. Dosage and frequency: 1 pack (3g), 3 packs per day (2 hours after morning, afternoon and evening meal)
Study NCT01579877 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo herbal extract granule
Description: The Yukmijihwang-tang_Placebo has the same form, color and flavor as experimental intervention (Yukmijihwang-tang). The dosage, frequency and duration is also the same as experimental intervention (Yukmijihwang-tang).
Study NCT00964522 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Nurse education and care program
Description: Random allocation of the patients in two arms according to the nursing cares. The arm A is the one of standard education and care. They consist of receiving programmed oral and written information by the specialist before initiating the chemotherapy treatment and before each cycle of treatment. Also, the patients will be able to ask for information to the nurses when they need it. Arm B is the one of experimental education and care. They consist of receiving oral and written information by the specialist before initiating the chemotherapy treatment and before each cycle. In addition, the patients assigned to arm B will receive programmed education and care about the chemotherapy by a Oncology nurse before the beginning of the treatment and in each cycle, in a specific nurse consultation.
Study NCT02219451 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: exercise training
Description: exercise training
Study NCT03692026 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Immediate implant placement
Description: implants will be placed in freshly extraction sockets with or without application of Hyaluronic acid and Melatonin mixture.
Study NCT03692026 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Immediate implant placement
Description: implants will be placed in freshly extraction sockets with or without application of Hyaluronic acid and Melatonin mixture.
Study NCT03692026 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Hyaluronic acid and Melatonin Mixture
Description: a mixture of hyaluronic acid and melatonin will be prepared and added topically to the implant surface, extraction socket and peri-implant area for the study group
Study NCT02035228 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Abdominal Stimulation - low / early
Description: Transcutaneous electrical stimulation applied to the abdominal wall muscles in synchronous with volitional exhalation.~Stimulation is applied at low stimulation current for the first half of exhalation
Study NCT02035228 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Abdominal stimulation - low/late
Description: Transcutaneous electrical stimulation applied to the abdominal wall muscles in synchronous with volitional exhalation.~Stimulation is applied at low stimulation current for the second half of exhalation
Study NCT02035228 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Abdominal Stimulation - low/full
Description: Transcutaneous electrical stimulation applied to the abdominal wall muscles in synchronous with volitional exhalation.~Stimulation is applied at low stimulation current throughout exhalation
Study NCT02035228 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Abdominal stimulation - med/early
Description: Transcutaneous electrical stimulation applied to the abdominal wall muscles in synchronous with volitional exhalation.~Stimulation is applied at medium stimulation current for the first half of exhalation
Study NCT02035228 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Abdominal stimulation - med/late
Description: Transcutaneous electrical stimulation applied to the abdominal wall muscles in synchronous with volitional exhalation.~Stimulation is applied at medium stimulation current for the second half of exhalation
Study NCT02035228 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Abdominal Stimulation - med/full
Description: Transcutaneous electrical stimulation applied to the abdominal wall muscles in synchronous with volitional exhalation.~Stimulation is applied at medium stimulation current throughout exhalation
Study NCT02035228 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Abdominal Stimulation - high/early
Description: Transcutaneous electrical stimulation applied to the abdominal wall muscles in synchronous with volitional exhalation.~Stimulation is applied at high stimulation current for the first half of exhalation
Study NCT02035228 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Abdominal Stimulation - high/late
Description: Transcutaneous electrical stimulation applied to the abdominal wall muscles in synchronous with volitional exhalation.~Stimulation is applied at hig stimulation current for the second half of exhalation
Study NCT02035228 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Abdominal Stimulation - high/full
Description: Transcutaneous electrical stimulation applied to the abdominal wall muscles in synchronous with volitional exhalation.~Stimulation is applied at high stimulation current throughout exhalation
Study NCT00276380 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: EGb761
Description: EGb761 (Tanakan) 40 mg tablets (2 tablets t.i.d. (3 times a day)) 240 mg/day for 6 months.
Study NCT00276380 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo 40 mg tablets (2 tablets t.i.d.) 240 mg/day for 6 months.
Study NCT01046084 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lansoprazole
Description: 30 mg Delayed-Release Capsule
Study NCT01046084 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Prevacid®
Description: 30 mg Delayed-Release Capsule
Study NCT03681977 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Zimmer MP Persona
Description: The medial pivot Persona® knee implant with a Medial Congruent™ Bearing
Study NCT03681977 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Zimmer Persona Knee-PS
Description: Persona the personalized knee system
Study NCT03155867 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Meal replacement
Description: The study interventions contain protein, carbohydrate and fat and are intended for use as complete meal replacements for weight loss.
Study NCT03261843 — intervention group
Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: autologous platelet rich plasma
Description: adding autologous platelet rich plasma to the bone graft harvested from the patient
Study NCT03261843 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: posterior lumbar interbody fusion without autologous platelet rich plasma
Description: performing posterior lumbar interbody fusion without using platelet rich plasma
Study NCT04456738 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Parent Training
Description: 16 weeks of of parent training led by a trained group facilitator
Study NCT00276380 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Acetylsalicylic acid
Description: Acetylsalicylic acid 325 mg/day (1 tablet once daily), for 6 months.
Study NCT00276380 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Acetylsalicylic acid
Description: Acetylsalicylic acid 325 mg/day (1 tablet once daily), for 6 months.
Study NCT03903341 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: fMRI
Description: bold signal in visual pathway
Study NCT03883958 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Erector Spinae Plane Block
Description: ESPB will be performed in sitting or lateral decubitus position. The target vertebral level will be correspond to the approximate mid-point of the extent of fractured ribs. The tip of the transverse process of the target vertebra will be identified using the high-frequency linear placed in cephalocaudal orientation about 3 cm to the spinous process. The skin and subcutaneous tissue will be infiltrated with 2-3 ml of 2% lignocaine. With the transducer fixed over the targeted TP, a 22-gauge 88-mm needle (Spinocan, B. Braun, Germany) will be advanced in-plane to the ultrasound beam in a cephalo-caudal direction to contact the TP. Correct needle tip position will be confirmed by doing alternating aspiration to confirm lack of inadvertent vascular puncture with injection of 1-2 ml of saline and visualizing linear fluid spread deep to erector spinae muscle, separating it from the TP. A bolus dose (2ml/segment) of plain bupivacaine 0.5% plus 4mg of Dexamethasone will be injected.
Study NCT03883958 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Paravertebral Block
Description: TPVB will be performed at a spinal level midway between the uppermost and the lowest fractured rib with the patient in sitting or lateral decubitus position (with patients lying on their unaffected side). The ultrasound-guided technique will be used. A high-frequency linear transducer will be used to confirm the levels of the fractured ribs. The most cephalad and most caudad fractured ribs will be identified first. The fractured rib in the middle will be then identified, and the rib will be then traced back medially. After skin and subcutaneous tissue infiltration with 2-3 ml of 2% lignocaine, a 22-gauge 88-mm needle (Spinocan, B. Braun, Germany) will be inserted in a lateral-to-medial direction until the needle tip entered the paravertebral space. 1-2 ml of Saline will be injected into the paravertebral space while observing the pleura being moved deeply. A bolus dose (2ml/segment) of plain bupivacaine 0.5% plus 4mg of Dexamethasone will be injected.
Study NCT01514279 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: HealthyCHANGE
Description: Cognitive behavioral strategies to address diet, physical activity, sedentary behavior and sleep for children.~It involves an intensive series of group sessions, followed by rotating monthly face-to-face meetings or phone calls.
Study NCT00519987 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: intranasal ketamine
Description: intranasal ketamine
Study NCT02719197 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AC-083
Description: Hard gelatin capsules for oral administration formulated at a strengths of 1, 10 and 100 mg
Study NCT02886065 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Hiltonol
Description: Intramuscular injection of Hiltonol (1 mg) administered Biweekly at the time of PVX-410 administration
Study NCT01514279 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: SystemCHANGE
Description: Intervention (based on systems improvement and choice architecture theories) System improvement and choice architecture theories seek to teach a set of skills using family self-designed experiments to redesign daily routines regarding eating, activity and sleep.~It involves an intensive series of group sessions, followed by rotating monthly face-to-face meetings or phone calls.
Study NCT02719197 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo capsules matching AC-083 capsules
Study NCT03896269 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Liposome-encapsulated Daunorubicin-Cytarabine
Description: Given IV
Study NCT04396860 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Contrast-enhanced Magnetic Resonance Imaging
Description: Undergo contrast-enhanced brain MRI
Study NCT04396860 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Contrast-enhanced Magnetic Resonance Imaging
Description: Undergo contrast-enhanced brain MRI
Study NCT04396860 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Ipilimumab
Description: Given IV